Ridge Biotechnologies
Latest round
- Seed
Last raised
- Sep 2026
Total raised
- $38M
Investors
- 3
About Ridge Biotechnologies
, based in the US, specializes in AI-driven enzyme and targeted drug design, focusing on innovative therapeutics that address complex medical challenges in the biopharmaceutical field. Founded in 2024 in Palo Alto, US, Ridge Biotechnologies, Inc. is dedicated to advancing biotechnology solutions. The company has undergone no major pivots or operational changes since its inception. In September 2026, Ridge Biotechnologies, Inc. The founder's specific history is not disclosed, but the company has established itself as an innovative player in the biotechnology sector. Ridge Biotechnologies specializes in AI-driven enzyme and targeted drug design, focusing on creating novel therapeutics that address complex medical challenges. Their product offerings include NativeLink enzymes, facilitating site-specific modification of proteins and peptides, and ProTrigger linkers that activate and release therapeutic payloads, reducing off-target toxicity in cancer therapy. The NativeLink – AXC product enables stable linkages in antibody-drug conjugates, enhancing therapeutic indices. Ridge Biotechnologies serves biopharmaceutical companies and research institutions mainly in North America and Europe, aiming to improve patient outcomes through advanced biotechnology solutions. Ridge Biotechnologies generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations seeking innovative drug development solutions. These involve customized agreements that allow clients to access Ridge's proprietary technologies and services, such as enzyme functionalization and targeted drug delivery systems. The flagship products, including NativeLink – AXC and ProTrigger linkers, add significant value in creating advanced therapeutics. Revenue is primarily derived from B2B relationships, enabling clients to leverage Ridge's proprietary platforms to enhance drug development processes. Looking ahead, Ridge Biotechnologies plans to expand its product offerings, focusing on enzyme-based therapeutic design and deploying a machine learning drug development platform.
Who invested in Ridge Biotechnologies
3 investors across 2 rounds
See all investors in Ridge Biotechnologies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ridge Biotechnologies
Who invested in Ridge Biotechnologies?
Ridge Biotechnologies has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ridge Biotechnologies raised?
Ridge Biotechnologies has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ridge Biotechnologies last raise money?
Ridge Biotechnologies's most recent round on record is a Seed, in Sep 2026.
What does Ridge Biotechnologies do?
, based in the US, specializes in AI-driven enzyme and targeted drug design, focusing on innovative therapeutics that address complex medical challenges in the biopharmaceutical field.
Where is Ridge Biotechnologies headquartered?
Ridge Biotechnologies is headquartered in Palo Alto, US.
Which VCs invest in companies like Ridge Biotechnologies?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ridge Biotechnologies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Ridge Biotechnologies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.